Sales Performance - Global H1 sales reached AUD$4.2 million, reflecting a 5% increase compared to the prior comparative period (pcp) [1] - Q2 sales amounted to AUD$2.2 million, showing an 11% increase over the prior quarter [1] - In Australia, H1 sales were AUD$3.3 million, up 13% on pcp, with Q2 sales at AUD$1.7 million, also up 11% on the prior quarter [1] - Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales surged to AUD$42 thousand, up 191% on the prior quarter [1] - U.S. H1 sales reached AUD$0.9 million, a 17% increase on pcp, with Q2 sales at AUD$0.4 million, up 8% on the prior quarter [1] Growth Drivers - Continued sales growth in Australia attributed to increased awareness from digital and social media marketing, same store growth, new store openings, and increased travel from South East Asia [3] - The launch of ProIBS ahead of schedule contributed to early sales opportunities, with listings secured in major pharmacy wholesalers [4] - U.S. sales growth driven by marketing initiatives including improved online presence and social media engagement [4] Future Prospects - Travelan is set to launch in Jean Coutu pharmacies in Canada in Q3 FY26, which is a leading pharmacy group in Quebec [6] - The company anticipates continued sales growth in Canada through in-store educational programs and promotions [5]

Core Insights - Immuron Limited has reported record sales for the financial year ending June 30, 2025, and is on track to exceed first quarter sales for FY24, with results expected in mid-October 2025 [3][10]. Sales Performance - The company achieved record sales up to the end of FY25 and anticipates surpassing FY24 first quarter sales [3]. - Travelan, a dietary supplement imported into the U.S., is not expected to be affected by new tariffs on pharmaceutical products [3][10]. Clinical Trial Updates - Immuron is developing three therapeutic products: IMM-124E (Travelan), IMM-529, and IMM-986 [4]. - Topline results for the Travelan clinical study are expected in October 2025, with the final patient visit anticipated in July 2025 [5][10]. - The company plans to request an end of Phase 2 meeting with the FDA for IMM-124E following the trial results, which will lead to a Phase 3 clinical program [6]. Revenue Projections - The base case yearly revenue for IMM-124E in the U.S. is projected at approximately US$102 million [7]. - The market for IMM-529 is estimated to reach peak revenues of around US$400 million [9]. Regulatory Milestones - Immuron plans to submit an Investigational New Drug (IND) application for IMM-529 to the FDA by mid-October 2025, which is necessary for starting a Phase 2 clinical program [8][10]. - The company is also progressing with initial pre-clinical studies for IMM-986, targeting Vancomycin-resistant enterococci (VRE), with completion expected by the end of 2025 [10][15]. Product Launch Plans - The launch of ProIBS, a treatment for Irritable Bowel Syndrome (IBS), is anticipated in Q4 of 2025, with a full launch planned for Q1 of 2026 [11][12]. - The IBS treatment market in Australia is projected to generate around A$221 million in 2025, with an annual growth rate of 3.28% [12].